Elbasvir/grazoprevir

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Elbasvir/grazoprevir
Combination of
Elbasvir NS5A inhibitor
Grazoprevir NS3/4A protease inhibitor
Clinical data
Trade names Zepatier
AHFS/Drugs.com entry
Legal status
Routes of
administration		 Oral (tablets)
Identifiers
ATC code J05AX68 (WHO) (temporary)

Elbasvir/grazoprevir (trade name Zepatier ZEP-ah-teer) is a fixed-dose two drug combination for the treatment of hepatitis C, containing 50 mg elbasvir (a hepatitis C virus NS5A inhibitor) and 100 mg grazoprevir (an NS3/4A protease inhibitor). It is used to treat chronic HCV genotypes 1 or 4 infection in both treatment-naïve and treatment-experienced patients.[1]

Both elbasvir and grazoprevir were developed by Merck & Co. The drug was approved on January 28, 2016.[2]

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.
  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
Retrieved from "https://infogalactic.com/w/index.php?title=Elbasvir/grazoprevir&oldid=702609769"